AI ScreeningAI ChatPricing
  1. US-listed companies
  2. Akari Therapeutics Plc
  3. Financials
  4. Cash and cash equivalents

Akari Therapeutics Plc【AKTX】

Market cap
$16.5B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 20243-30.85%
Dec 31, 20234-70.98%
Dec 31, 202213+41.54%
Dec 31, 20219-33.40%
Dec 31, 202014+145.23%
Dec 31, 20196-3.96%
Dec 31, 20186-78.77%
Dec 31, 201728-17.57%
Dec 31, 201634-50.52%
Dec 31, 201569+1008.75%
Dec 31, 20146-18.82%
Dec 31, 20138

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)